Institutional investors

A major player in private equity and infrastructure

15 years’ experience servicing institutional investors

  • A range of FPCI funds (French commingled fund structure) and expertise in dedicated mandates for major European institutional investors
  • Extensive coverage of all aspects of private equity
  • Stable, first-rate performance

Differentiated deal flow

  • Over 1,000 qualified projects reviewed per year
  • Regional opportunities seized ahead of the market thanks to the team’s personal network of contacts and its historical ties to the Crédit Agricole Group
  • Strong regional roots giving it first-class access to primary transactions

A personalised relationship and active support

  • Integrated support teams offering best-in-class services
  • Close relationship with investors
  • A dedicated client access on the corporate website
Expertises
Omnes Capital supports companies at every stage of their growth, from start-ups to mature businesses
NewsRoom
Press release
07 March 2006
Crédit Agricole Private Equity sells Logitrade stake
Crédit Agricole Private Equity sells Logitrade stake
Press release
16 February 2006
CDC Entreprises Capital to take over Marc Orian, France's leading watch and jewellery chain
CDC Entreprises Capital to take over Marc Orian, France's leading watch and jewellery chain
Press release
18 January 2006
Credit Agricole Private Equity sells its stake in Ingérop
Credit Agricole Private Equity sells its stake in Ingérop
Press release
12 October 2005
Crédit Agricole Private Equity’s Venture Capital division expands its Information and Communications Technology team
Crédit Agricole Private Equity’s Venture Capital division expands its Information and Communications Technology team
Press release
18 July 2005
XENTION RAISES £11 MILLION IN PRIVATE EQUITY PLACEMENT
XENTION RAISES £11 MILLION IN PRIVATE EQUITY PLACEMENT
Press release
12 April 2005
Crédit Agricole Private Equity’s Venture Capital division expands its Biotechnology team
Crédit Agricole Private Equity’s Venture Capital division expands its Biotechnology team

Pages